PT - JOURNAL ARTICLE AU - Pascal J. Goldschmidt-Clermont TI - COVID19 Real-World Data for the US and Lessons to Re-Open Business AID - 10.1101/2020.06.02.20120618 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.02.20120618 4099 - http://medrxiv.org/content/early/2020/06/10/2020.06.02.20120618.short 4100 - http://medrxiv.org/content/early/2020/06/10/2020.06.02.20120618.full AB - In March of 2020, the COVID19 pandemic had expanded to the United States of America (US). Companies designated as “essential” for the US had to maintain productivity in spite of the growing threat created by the SARS-CoV-2 virus. With this report, we present the response of one such company, the Lennar Corporation, a major homebuilder in the US. Within days, Lennar had implemented a morning health check via its enterprise resource planning system, to identify associates (employees) who were sick, or not in their “usual state of health”. With this survey, Lennar was able to ensure that no one sick would show up to work, and instead, would self-quarantine at home. Furthermore, with thorough contact tracking, associates exposed to COVID19 patients (suspected or RT-PCR test-confirmed), were also asked to self-quarantine. This survey, in addition to other safety measures, such as an overhaul of the company with nearly 50% of the company working from home, prolific communication, and many more measures, Lennar was able to function safely for its associates and successfully as an enterprise. The data that we present here are “real world data” collected in the context of working throughout a dreadful pandemic, and the lessons learned could be helpful to other companies that are preparing to return to work.Competing Interest StatementDr. Pascal J. Goldschmidt-Clermont serves as Chief Medical Officer for Lennar CorporationClinical TrialNot Human ResearchFunding StatementThe survey was supported by Lennar CorporationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not Human Research (see attached letter from IRB)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll anonymized data is available upon request